Cookies?
Library Header Image
LSE Research Online LSE Library Services

Snake oil or super drug: how have regulators and payers perceived new medicines that target asymptomatic conditions?

Needham, Brian Richard (2023) Snake oil or super drug: how have regulators and payers perceived new medicines that target asymptomatic conditions? Health Technology Assessment in Action, 7 (3). ISSN 2645-3835

[img] Text (Needham_snake-oil-or-super-drug--published) - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (289kB)

Identification Number: 10.18502/htaa.v7i3.14208

Abstract

Context: Assess how relevant precedent within the European Medicines Agency (EMA) (a key regulator) and the National Institute for Health and Care Excellence (NICE) (a key health technology assessment (HTA) body) can provide insights into how such novel medicines targeting asymptomatic conditions can be brought to market from both a regulatory and payer perspective. Methods: All phase 2 or phase 3 clinical trials with keywords such as asymptomatic, pre-symptomatic, subclinical, premanifest, or preclinical keywords were downloaded from clinicaltrials.gov. Trials were cleaned to identify those for novel medicines with a primary focus on treating asymptomatic conditions. The EMA and NICE report for such drugs were downloaded online in December 2021 and analyzed to understand how they assessed the evidence. Results: Two hundred seventy-eight clinical trials were identified. Of those, only 8 had relevant matching reports from the EMA or NICE, 7 received a positive review from the EMA, and 4 received a positive recommendation from the NICE. Those who received positive recommendations showed or were assumed to show statistically significant survival benefits given the short life expectancy of untreated patients. Conclusions: There is no precedent within the EMA or NICE for approving or funding new medicines for asymptomatic patients where survival benefits cannot be established. Additional research is warranted to understand how regulatory and payer agencies can prepare for future generations of innovative medicines.

Item Type: Article
Official URL: https://publish.kne-publishing.com/index.php/HTAA/...
Additional Information: © 2021 Tehran University of Medical Sciences.
Divisions: LSE
Subjects: R Medicine > RM Therapeutics. Pharmacology
Date Deposited: 21 May 2024 08:24
Last Modified: 17 Jul 2024 07:06
URI: http://eprints.lse.ac.uk/id/eprint/123536

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics